[BMJ Publishing Group Ltd and European League Against Rheumatism Annual European Congress of Rheumatology, 14–17 June, 2017 - ()] Oral Presentations - OP0202 Efficacy and safety of tofacitinib, an oral janus kinase inhibitor, in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: opal beyond, a randomised, double-blind, placebo-controlled, phase 3 trial
Gladman, DD, Rigby, WFC, Azevedo, VF, Behrens, F, Blanco, R, Kaszuba, A, Kudlacz, E, Wang, C, Menon, S, Hendrikx, T, Kanik, KSLanguage:
english
DOI:
10.1136/annrheumdis-2017-eular.2443
File:
PDF, 1.02 MB
english